HEMOFIL M
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- HEMOFIL M
- Generic name
- ANTIHEMOPHILIC FACTOR HUMAN
- Manufacturer
- Takeda Pharmaceuticals America, Inc.
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- b8953ff7-3bba-4a0b-a486-f26fb81f05d9
- SPL ID
- 15c108eb-91a2-4058-9d08-cc1168ee741d
- Version
- 15
- Effective date
- 2025-03-06
- Source export date
- 2026-11-13
- Source partition
- 10
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:15:32
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 101448 | derived:openfda.application_number |
| application number | BLA101448 | openfda.application_number | |
| brand name | HEMOFIL M | openfda.brand_name | |
| generic name | ANTIHEMOPHILIC FACTOR HUMAN | openfda.generic_name | |
| manufacturer name | Takeda Pharmaceuticals America, Inc. | openfda.manufacturer_name | |
| ndc | package | 0944-3940-02 | openfda.package_ndc |
| ndc | package | 0944-3947-01 | openfda.package_ndc |
| ndc | package | 0944-3946-02 | openfda.package_ndc |
| ndc | package | 0944-3942-02 | openfda.package_ndc |
| ndc | package | 64764-516-10 | openfda.package_ndc |
| ndc | package | 0944-3943-01 | openfda.package_ndc |
| ndc | package | 0944-3944-02 | openfda.package_ndc |
| ndc | package | 0944-3941-01 | openfda.package_ndc |
| ndc | package | 0944-3945-01 | openfda.package_ndc |
| ndc | product | 0944-3940 | openfda.product_ndc |
| ndc | product | 0944-3946 | openfda.product_ndc |
| ndc | product | 0944-3944 | openfda.product_ndc |
| ndc | product | 0944-3942 | openfda.product_ndc |
| ndc11 | package | 00944394002 | derived:openfda.package_ndc |
| ndc11 | package | 64764051610 | derived:openfda.package_ndc |
| ndc11 | package | 00944394202 | derived:openfda.package_ndc |
| ndc11 | package | 00944394602 | derived:openfda.package_ndc |
| ndc11 | package | 00944394501 | derived:openfda.package_ndc |
| ndc11 | package | 00944394701 | derived:openfda.package_ndc |
| ndc11 | package | 00944394101 | derived:openfda.package_ndc |
| ndc11 | package | 00944394402 | derived:openfda.package_ndc |
| ndc11 | package | 00944394301 | derived:openfda.package_ndc |
| rxcui | 1718965 | openfda.rxcui | |
| rxcui | 1718962 | openfda.rxcui | |
| spl id | 15c108eb-91a2-4058-9d08-cc1168ee741d | id | |
| spl set id | b8953ff7-3bba-4a0b-a486-f26fb81f05d9 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS Hypersensitivity Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with HEMOFIL M and have been manifested by bronchospasm, dyspnea, hypotension, chest pain, facial edema, urticaria, rash, flushing, pruritus, and nausea. Neutralizing Antibodies The development of neutralizing antibodies (inhibitors) to Factor VIII is a known complication of the treatment of patients with Hemophilia A. Inhibitors have predominantly been reported in previously untreated patients. The risk of developing inhibitors is correlated to the extent of exposure to Factor VIII, the risk being highest within the first 20 exposure days, and to other genetic and environmental factors. The risk for inhibitor development depends on a number of factors relating to the characteristics of the patient (e.g., type of the Factor VIII gene mutation, family history, ethnicity), which are believed to represent the most significant risk factors for inhibitor formation. Transmission of Infectious Agents Because HEMOFIL M is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens. All infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . The physician should discuss the risks and benefits of this product with the patient. Individuals who receive infusions of blood or plasma products may develop signs and/or symptoms of some viral infections, particularly non-A, non-B hepatitis. As indicated under Clinical Pharmacology , however, a group of such patients treated with HEMOFIL M did not demonstrate signs or symptoms of non-A, non-B hepatitis over observation periods ranging from three to nine months.
warnings
Hypersensitivity Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with HEMOFIL M and have been manifested by bronchospasm, dyspnea, hypotension, chest pain, facial edema, urticaria, rash, flushing, pruritus, and nausea.
warnings
Neutralizing Antibodies The development of neutralizing antibodies (inhibitors) to Factor VIII is a known complication of the treatment of patients with Hemophilia A. Inhibitors have predominantly been reported in previously untreated patients. The risk of developing inhibitors is correlated to the extent of exposure to Factor VIII, the risk being highest within the first 20 exposure days, and to other genetic and environmental factors. The risk for inhibitor development depends on a number of factors relating to the characteristics of the patient (e.g., type of the Factor VIII gene mutation, family history, ethnicity), which are believed to represent the most significant risk factors for inhibitor formation.
warnings
Transmission of Infectious Agents Because HEMOFIL M is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens. All infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . The physician should discuss the risks and benefits of this product with the patient. Individuals who receive infusions of blood or plasma products may develop signs and/or symptoms of some viral infections, particularly non-A, non-B hepatitis. As indicated under Clinical Pharmacology , however, a group of such patients treated with HEMOFIL M did not demonstrate signs or symptoms of non-A, non-B hepatitis over observation periods ranging from three to nine months.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Adverse Reactions from Clinical Trials The adverse reactions presented in this section have been identified based on clinical trial experience with HEMOFIL M in patients previously treated with other Factor VIII concentrates or blood products (N = 74), and previously untreated patients (PUPs; N = 50). Clinical Trial Adverse Reactions System Organ Class (SOC) Preferred MedDRA Term Number of Cases (Frequency Percentage) BLOOD AND LYMPHATIC SYSTEM DISORDERS Factor VIII inhibition 3 (5.7%) In a study that included 43 evaluable PUPs and 10 minimally treated patients (MTPs), i.e., patients with a single exposure to other Factor VIII concentrates or blood products, 3 of the total of 53 patients (5.7%) developed an inhibitor while on study. NERVOUS SYSTEM DISORDERS Dizziness 1 (0.8%) Headache 1 (0.8%) Dysgeusia 1 (0.8%) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS Pyrexia 1 (0.8%) Infusion site inflammation 2 (1.6%) HEMOFIL M was administered to 11 patients previously untreated with Antihemophilic Factor (Human). They have shown no signs of hepatitis or HIV infection following three to nine months of evaluation. A study of 25 patients treated with HEMOFIL M and monitored for three to six months has demonstrated no evidence of antibody response to mouse protein. More than 1,000 infusions of HEMOFIL M have been administered during the clinical trials. Reported events included a single episode each of chest tightness, fuzziness and dizziness, and one patient reported an unusual taste after each infusion. Post-marketing Adverse Reactions In addition to clinical trials, the following adverse reactions have been reported in the post-marketing experience, listed by MedDRA System Organ Class (SOC), then by Preferred Term. Immune System Disorders : anaphylactic reaction, hypersensitivity Eye Disorders : visual impairment, ocular hyperemia Cardiac Disorders : cyanosis, bradycardia, tachycardia Vascular Disorders : hypotension, flushing Respiratory, Thoracic, and Mediastinal Disorders : bronchospasm, dyspnea, cough, hyperventilation Gastrointestinal Disorders : diarrhea, vomiting, nausea, abdominal pain Skin and Subcutaneous Tissue Disorders : urticaria, rash, pruritus, hyperhidrosis Musculoskeletal and Connective Tissue Disorders : musculoskeletal pain General Disorders and Administration Site Conditions : facial edema, edema, chills, fatigue, chest pain, irritability
adverse reactions
Adverse Reactions from Clinical Trials The adverse reactions presented in this section have been identified based on clinical trial experience with HEMOFIL M in patients previously treated with other Factor VIII concentrates or blood products (N = 74), and previously untreated patients (PUPs; N = 50). Clinical Trial Adverse Reactions System Organ Class (SOC) Preferred MedDRA Term Number of Cases (Frequency Percentage) BLOOD AND LYMPHATIC SYSTEM DISORDERS Factor VIII inhibition 3 (5.7%) In a study that included 43 evaluable PUPs and 10 minimally treated patients (MTPs), i.e., patients with a single exposure to other Factor VIII concentrates or blood products, 3 of the total of 53 patients (5.7%) developed an inhibitor while on study. NERVOUS SYSTEM DISORDERS Dizziness 1 (0.8%) Headache 1 (0.8%) Dysgeusia 1 (0.8%) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS Pyrexia 1 (0.8%) Infusion site inflammation 2 (1.6%) HEMOFIL M was administered to 11 patients previously untreated with Antihemophilic Factor (Human). They have shown no signs of hepatitis or HIV infection following three to nine months of evaluation. A study of 25 patients treated with HEMOFIL M and monitored for three to six months has demonstrated no evidence of antibody response to mouse protein. More than 1,000 infusions of HEMOFIL M have been administered during the clinical trials. Reported events included a single episode each of chest tightness, fuzziness and dizziness, and one patient reported an unusual taste after each infusion.
adverse reactions
Post-marketing Adverse Reactions In addition to clinical trials, the following adverse reactions have been reported in the post-marketing experience, listed by MedDRA System Organ Class (SOC), then by Preferred Term. Immune System Disorders : anaphylactic reaction, hypersensitivity Eye Disorders : visual impairment, ocular hyperemia Cardiac Disorders : cyanosis, bradycardia, tachycardia Vascular Disorders : hypotension, flushing Respiratory, Thoracic, and Mediastinal Disorders : bronchospasm, dyspnea, cough, hyperventilation Gastrointestinal Disorders : diarrhea, vomiting, nausea, abdominal pain Skin and Subcutaneous Tissue Disorders : urticaria, rash, pruritus, hyperhidrosis Musculoskeletal and Connective Tissue Disorders : musculoskeletal pain General Disorders and Administration Site Conditions : facial edema, edema, chills, fatigue, chest pain, irritability
adverse reactions table
<table width="100%"><col width="35%"/><col width="33%"/><col width="32%"/><tbody><tr><td align="center" colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="top"><paragraph><content styleCode="bold">Clinical Trial Adverse Reactions</content></paragraph></td></tr><tr><td align="center" styleCode="Lrule Botrule " valign="top"><paragraph><content styleCode="bold">System Organ Class (SOC)</content></paragraph></td><td align="center" styleCode="Lrule Botrule " valign="top"><paragraph><content styleCode="bold">Preferred MedDRA Term</content></paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">Number of Cases</content></paragraph><paragraph><content styleCode="bold">(Frequency</content></paragraph><paragraph><content styleCode="bold">Percentage)</content></paragraph></td></tr><tr><td styleCode="Lrule Botrule " valign="top"><paragraph><content styleCode="bold">BLOOD AND LYMPHATIC</content></paragraph><paragraph><content styleCode="bold">SYSTEM DISORDERS</content></paragraph></td><td styleCode="Lrule Botrule " valign="middle"><paragraph>Factor VIII inhibition</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="middle"><paragraph>3 (5.7%)<footnote ID="_RefID0B1990E431FA4641B20FACAB3F077453">In a study that included 43 evaluable PUPs and 10 minimally treated patients (MTPs), i.e., patients with a single exposure to other Factor VIII concentrates or blood products, 3 of the total of 53 patients (5.7%) developed an inhibitor while on study.</footnote></paragraph></td></tr><tr><td rowspan="3" styleCode="Lrule Botrule " valign="top"><paragraph><content styleCode="bold">NERVOUS SYSTEM DISORDERS</content></paragraph></td><td styleCode="Lrule Botrule " valign="top"><paragraph>Dizziness</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>1 (0.8%)</paragraph></td></tr><tr><td styleCode="Lrule Botrule " valign="top"><paragraph>Headache</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>1 (0.8%)</paragraph></td></tr><tr><td styleCode="Lrule Botrule " valign="top"><paragraph>Dysgeusia</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>1 (0.8%)</paragraph></td></tr><tr><td rowspan="2" styleCode="Lrule Botrule " valign="top"><paragraph><content styleCode="bold">GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</content></paragraph></td><td styleCode="Lrule Botrule " valign="top"><paragraph>Pyrexia</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>1 (0.8%)</paragraph></td></tr><tr><td styleCode="Botrule Lrule " valign="top"><paragraph>Infusion site inflammation</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>2 (1.6%)</paragraph></td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.